{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:41:29Z","timestamp":1783464089369,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"AstraZeneca Pharma India Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s13300-025-01770-3","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T07:36:15Z","timestamp":1753083375000},"page":"1841-1859","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Preferences for Novel Type\u00a02 Diabetes Oral Medications: Insights from the Asian Diabetes Patient Preference Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Mangesh","family":"Tiwaskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chii-Min","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apeksha","family":"Bhandary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"1770_CR1","unstructured":"Global Burden of Disease Collaborative Network. Global burden of disease study 2019. Results. Institute for Health Metrics and Evaluation. 2020. Accessed on 24 June 2024. https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"1770_CR2","unstructured":"International Diabetes Federation. IDF diabetes atlas, 9th edn. Brussels. Belgium; 2021. Accessed on 24 June 2024. https:\/\/www.diabetesatlas.org."},{"key":"1770_CR3","doi-asserted-by":"crossref","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334.","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"1770_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157: 107843.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1770_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2022.104159","volume":"52","author":"L Gnudi","year":"2023","unstructured":"Gnudi L. Renal disease in patients with type\u00a02 diabetes: magnitude of the problem, risk factors and preventive strategies. Presse Med. 2023;52(1):104159.","journal-title":"Presse Med"},{"issue":"1","key":"1770_CR6","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type\u00a02 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"key":"1770_CR7","unstructured":"National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guideline NG28. Accessed on 24 June 2024. https:\/\/www.nice.org.uk\/guidance\/ng238."},{"key":"1770_CR8","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management, NICE guideline NG28. Accessed on 24 June 2024. https:\/\/www.nice.org.uk\/guidance\/ng28."},{"issue":"1","key":"1770_CR9","doi-asserted-by":"publisher","first-page":"6156","DOI":"10.1038\/s41598-019-42531-0","volume":"9","author":"O Horakova","year":"2019","unstructured":"Horakova O, Kroupova P, Bardova K, et al. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Sci Rep. 2019;9(1):6156.","journal-title":"Sci Rep"},{"issue":"11","key":"1770_CR10","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type\u00a02 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"issue":"3","key":"1770_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","volume":"183","author":"E D\u2019Andrea","year":"2023","unstructured":"D\u2019Andrea E, Wexler DJ, Kim SC, Paik JM, Alt E, Patorno E, et al. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type\u00a02 diabetes and varying baseline HbA1c levels. JAMA Intern Med. 2023;183(3):242\u201354.","journal-title":"JAMA Intern Med"},{"issue":"9","key":"1770_CR12","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/dom.14055","volume":"22","author":"F Giorgino","year":"2020","unstructured":"Giorgino F, Vora J, Fenici P, Solini A.\u00a0Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type\u00a02 diabetes: does it apply to all patients? Diabetes Obes Metab. 2020;22(9):1481\u201395.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1770_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type\u00a02 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"10","key":"1770_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","volume":"13","author":"DI Patoulias","year":"2021","unstructured":"Patoulias DI, Boulmpou A, Teperikidis E, et al. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials. World J Cardiol. 2021;13(10):585\u201392.","journal-title":"World J Cardiol"},{"key":"1770_CR15","doi-asserted-by":"publisher","unstructured":"Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type\u00a02 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev. 2017;33(1). https:\/\/doi.org\/10.1002\/dmrr.2818.","DOI":"10.1002\/dmrr.2818"},{"key":"1770_CR16","doi-asserted-by":"publisher","first-page":"204209862198913","DOI":"10.1177\/2042098621989134","volume":"12","author":"R Pelletier","year":"2021","unstructured":"Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble JM, et al. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews. Ther Adv Drug Saf. 2021;12:2042098621989134.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"1770_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jcjd.2021.04.006","volume":"46","author":"M Colacci","year":"2022","unstructured":"Colacci M, Fralick J, Odutayo A, Fralick M. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type\u00a02 diabetes: a systematic review and meta-analysis. Can J Diabetes. 2022;46(1):10-15.e2.","journal-title":"Can J Diabetes"},{"key":"1770_CR18","unstructured":"ICMR guidelines for management of type 2 diabetes 2018. Indian Council of Medical Research, New Delhi. https:\/\/main.icmr.nic.in\/sites\/default\/files\/guidelines\/ICMR_GuidelinesType2diabetes2018_0.pdf."},{"issue":"1","key":"1770_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12902-016-0122-x","volume":"16","author":"JM Lopez","year":"2016","unstructured":"Lopez JM, Katic BJ, Fitz-Randolph M, Jackson RA, Chow W, Mullins CD. Understanding preferences for type\u00a02 diabetes mellitus self-management support through a patient-centered approach: a 2-phase mixed-methods study. BMC Endocr Disord. 2016;16(1):41.","journal-title":"BMC Endocr Disord"},{"key":"1770_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12875-015-0230-0","volume":"16","author":"H den Ouden","year":"2015","unstructured":"den Ouden H, Vos RC, Reidsma C, Rutten GE. Shared decision making in type\u00a02 diabetes with a support decision tool that takes into account clinical factors, the intensity of treatment and patient preferences: design of a cluster randomised (OPTIMAL) trial. BMC Fam Pract. 2015;16:27.","journal-title":"BMC Fam Pract"},{"issue":"7","key":"1770_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jval.2020.01.023","volume":"23","author":"S Ozdemir","year":"2020","unstructured":"Ozdemir S, Baid D, Verghese NR, et al. Patient preferences for medications in managing type\u00a02 diabetes mellitus: a discrete choice experiment. Value Health. 2020;23(7):842\u201350.","journal-title":"Value Health"},{"key":"1770_CR22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2147\/PPA.S355638","volume":"16","author":"JE Costa Gil","year":"2022","unstructured":"Costa Gil JE, Garnica Cu\u00e9llar JC, Perez Terns P. et al. Patients\u2019 preference between DPP4i and SGLT2i for type\u00a02 diabetes treatment: a cross-sectional evaluation. Patient Prefer Adherence. 2022;16:1201\u201311.","journal-title":"Patient Prefer Adherence"},{"issue":"36","key":"1770_CR23","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e230","volume":"36","author":"KA Lee","year":"2021","unstructured":"Lee KA, Jin HY, Kim YJ, Im YJ, Kim EY, Park TS. Treatment patterns of type\u00a02 diabetes assessed using a common data model based on electronic health records of 2000\u20132019. J Korean Med Sci. 2021;36(36):e230.","journal-title":"J Korean Med Sci"},{"issue":"3","key":"1770_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.diabres.2013.12.052","volume":"103","author":"S Geerlings","year":"2014","unstructured":"Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S.\u00a0Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373\u201381.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1770_CR25","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/dom.13152","volume":"20","author":"N Inagaki","year":"2018","unstructured":"Inagaki N, Harashima SI, Kaku K, et al. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type\u00a02 diabetes mellitus. Diabetes Obes Metab. 2018;20(4):812\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1770_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/dom.13531","volume":"21","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Comparative risk of genital infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2019;21(2):434\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1770_CR27","doi-asserted-by":"publisher","first-page":"336","DOI":"10.7570\/jomes21061","volume":"30","author":"YK Cho","year":"2021","unstructured":"Cho YK, Kim YJ, Jung CH. Effect of sodium-glucose cotransporter 2 inhibitors on weight reduction in overweight and obese populations without diabetes: a systematic review and a meta-analysis. J Obes Metab Syndr. 2021;30(4):336\u201344.","journal-title":"J Obes Metab Syndr"},{"key":"1770_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"YM Gao","year":"2022","unstructured":"Gao YM, Feng ST, Wen Y, Tang TT, Wang B, Liu BC.\u00a0Cardiorenal protection of SGLT2 inhibitors\u2013perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215.","journal-title":"EBioMedicine"},{"issue":"3","key":"1770_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","volume":"8","author":"JS Aguilar-Gallardo","year":"2022","unstructured":"Aguilar-Gallardo JS, Correa A, Contreras JP. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):311\u201321.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1770_CR30","unstructured":"Philippine Practice Guidelines for the Diagnosis and Management of Diabetes. Accessed on 24 June 2024. https:\/\/diabetesphilippines.org\/HOME\/Forms\/clinical_practice_guidelines_draft.pdf."},{"key":"1770_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3389\/fendo.2018.00479","volume":"9","author":"AE Caballero","year":"2018","unstructured":"Caballero AE. The \u201cA to Z\u201d of managing type\u00a02 diabetes in culturally diverse populations. Front Endocrinol (Lausanne). 2018;9:479.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"1770_CR32","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/dom.14708","volume":"24","author":"ZY Peng","year":"2022","unstructured":"Peng ZY, Yang CT, Ou HT, Kuo S. Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type\u00a02 diabetes with and without established cardiovascular diseases: a model-based simulation analysis using 10-year real-world data and targeted literature review. Diabetes Obes Metab. 2022;24(7):1328\u201337.","journal-title":"Diabetes Obes Metab"},{"key":"1770_CR33","doi-asserted-by":"publisher","unstructured":"Pushkar M, Jain S, Mathur R, Shoaib M, Mathur A. Comparison between the efficacy of SGLT2 inhibitors versus DPP4 inhibitors in Indian population: a systematic review. J Popl Ther Clin Pharmacol. 2024;31(1):605\u201316. https:\/\/doi.org\/10.53555\/jptcp.v31i1.4056.","DOI":"10.53555\/jptcp.v31i1.4056"},{"issue":"5","key":"1770_CR34","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s13300-022-01219-x","volume":"13","author":"M Chadha","year":"2022","unstructured":"Chadha M, Das AK, Deb P, et al. Expert opinion: optimum clinical approach to combination-use of SGLT2i + DPP4i in the Indian diabetes setting. Diabetes Ther. 2022;13(5):1097\u2013114.","journal-title":"Diabetes Ther"},{"issue":"2","key":"1770_CR35","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40200-019-00449-4","volume":"18","author":"M Toroski","year":"2019","unstructured":"Toroski M, Kebriaeezadeh A, Esteghamati A, Karyani AK, Abbasian H, Nikfar S. Patient and physician preferences for type\u00a02 diabetes medications: a systematic review. J Diabetes Metab Disord. 2019;18(2):643\u201356.","journal-title":"J Diabetes Metab Disord"},{"issue":"6","key":"1770_CR36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s13300-017-0326-8","volume":"8","author":"C Mansfield","year":"2017","unstructured":"Mansfield C, Sikirica MV, Pugh A, et al. Patient preferences for attributes of type\u00a02 diabetes mellitus medications in Germany and Spain: an online discrete-choice experiment survey. Diabetes Ther. 2017;8(6):1365\u201378.","journal-title":"Diabetes Ther"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01770-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01770-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01770-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:15:35Z","timestamp":1757261735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01770-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1770"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01770-3","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"15 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Mangesh Tiwaskar: Nothing to disclose. Dr Chii-Min Hwu: Received manuscript development funding for the current study from AstraZeneca, grant support from Sanofi, Eli Lilly, MSD, consulting fees from Novo Nordisk, honoraria and speaker bureau fees from Eli Lilly, Sanofi, Zuellig, Amgen. Dr Marcelo Lim: Received support for medical writing from AstraZeneca. Dr Apeksha Bhandary and Dr Iris Chang are employees of AstraZeneca Pharma India Limited and AstraZeneca Pharma Taiwan Limited and may own stock and stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics Review Board and written informed consent was obtained from participants. We obtained approval ethics review board for all the three countries, St. Luke\u2019s Medical Centre Institutional Ethics Review Committee for Philippines (IEC no. D1690R00082\u2014PH 5503 IRB), Chang Gung Medical Foundation Institutional Review Board Certificate of Clinical Trial\/Research Consent for Taiwan (IEC no. D1690R00082_7406_CCH), and Conscience Independent Ethics Committee review board for India (IEC no. D1690R00082).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}